Literature DB >> 6520744

Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats.

N Terao, D D Shen.   

Abstract

The effect of experimental renal failure on the intravenous and oral pharmacokinetics of l-propranolol was studied in rats. Renal failure was induced by a single intravenous injection of uranyl nitrate (5 mg/kg). Pharmacokinetic studies were carried out on the fifth day after injection of the renal toxin (renal failure group) or saline (control group). Serum concentration time course of l-propranolol was characterized after a single intravenous or oral dose as well as after five consecutive doses of the drug given at 3-hr intervals. During repetitive intravenous drug administration, steady state was reached by the second dose, i.e., within 6 hr after initiation of repetitive dosing. No significant difference in the serum concentration time course of l-propranolol was observed between control and renal failure animals. In both groups the AUC over the steady-state dosing interval was on the average 21-27% higher than the AUC after a single dose, indicating a slight decrease in the systemic clearance of l-propranolol during repetitive intravenous drug administration. An approximately two- to three-fold higher serum l-propranolol concentration was observed in renal failure animals as compared to the normal controls after both single or repetitive oral dosing. The apparent reduction in oral clearance probably reflected an inhibition of the hepatic first-pass metabolism of l-propranolol in the renal failure rat. An unexpectedly high and protracted accumulation of serum l-propranolol concentration was observed during repetitive oral drug administration. Continuing accumulation was still evident after the fifth oral dose, i.e., a period of 15 hr or approximately 10 half-lives. The mean AUC over the last dosing interval was 32.0 and 17.8 times higher than the predicted steady-state estimate based on single oral dose data for control and renal failure rats, respectively. The substantial reduction in the oral clearance during repetitive drug administration may be due to an auto-inhibition of l-propranolol metabolism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6520744     DOI: 10.1007/bf01060127

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  22 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  CHRONIC INTRAVENOUS CANNULAS FOR RATS.

Authors:  J R WEEKS; J D DAVIS
Journal:  J Appl Physiol       Date:  1964-05       Impact factor: 3.531

3.  Pharmacokinetics of oral propranolol in chronic renal disease.

Authors:  D T Lowenthal; W A Briggs; T P Gibson; H Nelson; W J Cirksena
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

4.  The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver.

Authors:  R A Branch; A S Nies; D G Shand
Journal:  Drug Metab Dispos       Date:  1973 Sep-Oct       Impact factor: 3.922

5.  Aromatic hydroxylation of propranolol. Stereochemical aspects of the formation of 4'-hydroxypropranolol in the rat.

Authors:  M L Powell; R R Wagoner; C H Chen; W L Nelson
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-12

6.  Massive propranolol metabolite retention during maintenance hemodialysis.

Authors:  W J Stone; T Walle
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

7.  Propranolol disposition in renal failure.

Authors:  A J Wood; R E Vestal; C L Spannuth; W J Stone; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

8.  Presystemic and systemic glucuronidation of propranolol.

Authors:  T Walle; T C Fagan; E C Conradi; U K Walle; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

9.  Glucuronidation of propranolol and 4'-hydroxypropranolol. Substrate specificity and stereoselectivity of rat liver microsomal glucuronyltransferases.

Authors:  J A Thompson; J E Hull; K J Norris
Journal:  Drug Metab Dispos       Date:  1981 Sep-Oct       Impact factor: 3.922

10.  Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter.

Authors:  N Terao; D D Shen
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

View more
  4 in total

1.  Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure.

Authors:  S H Kim; H J Shim; W B Kim; M G Lee
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Sensory pudendal nerve stimulation increases bladder capacity through sympathetic mechanisms in cyclophosphamide-induced cystitis rats.

Authors:  Eric J Gonzalez; Warren M Grill
Journal:  Neurourol Urodyn       Date:  2018-10-23       Impact factor: 2.696

3.  Changes in neurotransmitter sensitivity in the mouse neocortical slice following propranolol and theophylline administration.

Authors:  J Mally; J H Connick; T W Stone
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

4.  Down-regulation of hepatic CYP3A in chronic renal insufficiency.

Authors:  Bhaskar Rege; Richard Krieg; Ning Gao; Mohamadi A Sarkar
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.